JP2007523188A - Ｃ−ｍｅｔ阻害薬及びｍ−ｔｏｒ阻害薬を使用する異常な細胞増殖の治療法 - Google Patents

Ｃ−ｍｅｔ阻害薬及びｍ−ｔｏｒ阻害薬を使用する異常な細胞増殖の治療法 Download PDF

Info

Publication number
JP2007523188A
JP2007523188A JP2006554283A JP2006554283A JP2007523188A JP 2007523188 A JP2007523188 A JP 2007523188A JP 2006554283 A JP2006554283 A JP 2006554283A JP 2006554283 A JP2006554283 A JP 2006554283A JP 2007523188 A JP2007523188 A JP 2007523188A
Authority
JP
Japan
Prior art keywords
cancer
aryl
cycloalkyl
met
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006554283A
Other languages
English (en)
Japanese (ja)
Inventor
ジー． クリステンセン，ジェイムズ
サルジア，ラビ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of JP2007523188A publication Critical patent/JP2007523188A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
JP2006554283A 2004-02-23 2005-02-22 Ｃ−ｍｅｔ阻害薬及びｍ−ｔｏｒ阻害薬を使用する異常な細胞増殖の治療法 Pending JP2007523188A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54685004P 2004-02-23 2004-02-23
PCT/US2005/005547 WO2005082411A1 (fr) 2004-02-23 2005-02-22 Methode de traitement d'une croissance cellulaire anormale au moyen d'inhibiteurs c-met et m-tor

Publications (1)

Publication Number Publication Date
JP2007523188A true JP2007523188A (ja) 2007-08-16

Family

ID=34910822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006554283A Pending JP2007523188A (ja) 2004-02-23 2005-02-22 Ｃ−ｍｅｔ阻害薬及びｍ−ｔｏｒ阻害薬を使用する異常な細胞増殖の治療法

Country Status (7)

Country Link
US (1) US20060035907A1 (fr)
EP (1) EP1720574A4 (fr)
JP (1) JP2007523188A (fr)
BR (1) BRPI0507834A (fr)
CA (1) CA2556025A1 (fr)
MX (1) MXPA06009547A (fr)
WO (1) WO2005082411A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515415A (ja) * 2008-03-21 2011-05-19 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
JP2015091237A (ja) * 2009-04-10 2015-05-14 チー，ハイヤン 新規抗老化剤及びそれらを同定する方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2481671T3 (es) * 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
WO2007106503A2 (fr) * 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Traitement combiné avec un inhibiteur de kinase egfr et un agent sensibilisant les cellules tumorales aux effets des inhibiteurs de kinase egfr
US20090029904A1 (en) * 2006-07-21 2009-01-29 Sean Oldham Compositions and methods for treatment of insulin-resistance diseases
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
US20090042906A1 (en) * 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
WO2009111529A2 (fr) * 2008-03-04 2009-09-11 Children's Medical Center Corporation Méthode de traitement d’une maladie polykystique des reins
EP2555766A4 (fr) 2010-04-06 2015-06-03 Univ Brigham Young Composés antimétastatiques
RS53818B1 (en) 2012-10-12 2015-06-30 Spirogen Sàrl PIROLOBENZODIAZEPINI I NJIHOVI conjugated
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
WO2018069289A1 (fr) 2016-10-11 2018-04-19 Medimmune Limited Conjugués anticorps-médicament associés à des agents thérapeutiques à médiation immunitaire
WO2018129364A1 (fr) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
WO2019224275A1 (fr) 2018-05-23 2019-11-28 Adc Therapeutics Sa Adjuvant moléculaire
WO2020010073A1 (fr) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
WO2022079211A1 (fr) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugués
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6599902B2 (en) * 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
ES2401330T3 (es) * 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515415A (ja) * 2008-03-21 2011-05-19 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
JP2015044847A (ja) * 2008-03-21 2015-03-12 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
JP2015091237A (ja) * 2009-04-10 2015-05-14 チー，ハイヤン 新規抗老化剤及びそれらを同定する方法

Also Published As

Publication number Publication date
BRPI0507834A (pt) 2007-07-10
EP1720574A4 (fr) 2009-09-09
MXPA06009547A (es) 2007-01-26
EP1720574A1 (fr) 2006-11-15
WO2005082411A1 (fr) 2005-09-09
CA2556025A1 (fr) 2005-09-09
US20060035907A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
JP2007523188A (ja) Ｃ−ｍｅｔ阻害薬及びｍ−ｔｏｒ阻害薬を使用する異常な細胞増殖の治療法
EP3903828A1 (fr) Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase
US10047078B2 (en) Aminothiazole compounds
US20090012085A1 (en) Dosage forms and methods of treatment using a tyrosine kinase inhibitor
AU2004226586B2 (en) Dosage forms comprising AG013736
US10464939B2 (en) Deuterated triazolopyridazine as a kinase modulator
ZA200506974B (en) Dosage forms comprising AG013736
TW202216207A (zh) 抗體-藥物結合物及cdk9抑制劑之組合
US20050182122A1 (en) Method of treating abnormal cell growth using indolinone compounds
Kornek et al. Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel
US20230256110A1 (en) Combination of antibody-drug conjugate and atm inhibitor
WO2023126822A1 (fr) Association d'un conjugué anticorps-médicament et d'un inhibiteur de rasg12c
CN114245753A (zh) 用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合
KR20230110558A (ko) 축합 피리미딘 화합물을 유효 성분으로 하는 뇌 이행성 종양 치료제
WO2021260583A1 (fr) Association d'un conjugué anticorps-médicament et d'un inhibiteur de la dna-pk
NZ733447B2 (en) A deuterated triazolopyridazine as a kinase modulator

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110329